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Prostate cancer is the second leading cause of cancer-related death among American 
men.  Substantial biological heterogeneity, however, makes it clinically challenging to predict tumor 
aggressiveness and determine the appropriate course of treatment.  Prognosis is currently estimated 
using measures of tumor stage, diagnostic prostate-specific antigen (PSA) level, and Gleason score 
(a quantitative measure of tissue architecture based on microscopic analysis).  Additional prognostic 
biomarkers could help to provide more accurate predictions of individual outcomes, and stratify 
patients for more precise care regimens.  The expression levels of cell cycle-regulated genes are 
commonly dysregulated in various cancer types, and have been associated with cancer 
aggressiveness and poor patient outcomes.   
Several commercial tests have been developed to evaluate gene expression in relation to prostate 
cancer progression.  These panels, however, were developed based on selected patient groups and 
the clinical utility of these tests has been questioned.  To see if cell cycle-regulated gene 
dysregulation might provide additional prognostic information for prostate cancer in a population-
based cohort, Drs. Rohina Rubicz and Janet Stanford and colleagues in the Public Health Sciences 
Division evaluated a panel of 30 cell cycle-regulated genes for differential expression in prostate 
cancer tumors. As recently reported in The Prostate, mean expression in these genes was 
associated with a twofold higher risk of lethal prostate cancer. 
The expression levels of cell cycle-regulated genes increase or decrease according to the timing and 
duration of the cell cycle.  These genes are important for normal growth and development, as they 
are involved in various processes necessary for cell duplication.  As such, these genes may be more 
highly expressed in actively dividing cells, such as within a tumor, with transcript levels reflecting the 
growth rate of the tumor.  Previous studies have used expression profiles of cell cycle-regulated 
genes to measure tumor aggressiveness and help inform prognostic groups in breast cancer and 
lymphoma, suggesting that a similar approach might be useful for classifying patients at risk for 
prostate cancer recurrence and death. 
The authors evaluated existing data and tumor samples from nearly 400 men diagnosed with 
prostate cancer in King County, Washington, who had undergone a radical prostatectomy.  Genome-
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wide gene expression profiling was performed on archived tumor tissue blocks from these patients, 
providing mRNA transcript levels for each individual.  The mean expression levels for a panel of 30 
candidate cell cycle-regulated genes were then evaluated for an association with prostate cancer 
recurrence or lethality, over an average 12.3 years of follow-up.   
The mean expression level of this gene panel was found to vary by prognostic group, with the lowest 
expression for the group of cases that did not recur, higher expression for the recurrence group, and 
highest expression for the group that progressed to metastatic or lethal prostate cancer.  These 
levels were then evaluated for an association with recurrence and lethality.  "The average 
expression level of these genes was associated with time to prostate cancer recurrence for patients 
with the highest expression levels," said lead author Dr. Rubicz (see figure).  "Similar results were 
observed when the analysis was limited to patients who progressed to lethal prostate cancer."  In 
addition, 10 of these genes individually demonstrated statistically significant differences in 
expression between the groups, highlighting potential targets for future investigation.   
These results suggest that gene expression of some or all of these genes may potentially be useful 
as a prognostic biomarker for prostate cancer.  "However, in our cohort the mRNA levels for this 
panel of genes did not substantially improve upon Gleason sum as a prognostic marker for overall 
prostate cancer recurrence," said Dr. Rubicz.  Thus while higher mean gene expression was 
associated with a twofold increase in risk of lethal prostate cancer in this study, further work is 
needed before this finding might be useful for informing clinical practice.  "The next step for this 
project will be to expand the analysis to include transcriptome-wide DASL array (Illumina, Inc.) data 
to identify top-ranked differentially expressed genes that may be clinically useful for stratifying 
patients into prognostic subgroups." 
Other Fred Hutch investigators contributing to this project were Drs. Shanshan Zhao, Jonathan 
Wright, Suzanne Kolb, Daniel Lin, and Peter Nelson. 
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Kaplan-Meier plot of time to prostate 
cancer recurrence (top) or death (bottom), 
according to the percentile distribution of 
the mean expression levels of 30 cell 
cycle-regulated genes. Hazard ratio (HR) 
and 95% confidence interval (95% CI) 
associated with a change from the 25th to 
the 75th percentile of mean expression 
level distribution. The adjusted HR 
adjusts for age at diagnosis, Gleason 
score, diagnostic prostate specific antigen 
level, and pathologic tumor stage. 
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